Viking Therapeutics VKTX offering, convertible notes and lawsuit news

Opinion · Devil's advocate

Fact-check-o-meter

Viking's data headlines come from small cohorts, and its releases skip the Ligand dispute and the buyback

The VK2735 results are real and placebo-controlled, but the headline figures in the September maintenance release come from arms of 12 to 13 patients in a study the registry lists as Phase 1 with a safety primary outcome. The 10-Q discloses a license dispute with Ligand over VK2809 and VK0214 and a $500 million buyback authorization that none of four reviewed releases mentions. Viking then raised about $548 million in September.

1. Science · weight medium

   22% headline comes from a 13-patient exploratory arm

   The company said: "22% Placebo-Adjusted Weight Loss Reported at Week 33 Following Weekly Dosing of VK2735 at 17.5 mg; No Plateau Observed" source

   The record says: The body of the same release describes the source as "An exploratory control arm in the study evaluated weight change in a cohort of participants who continued receiving weekly VK2735 doses of 17.5 mg (n=13)." The release gives no registry number; the entry that appears to match (NCT07838740, start November 2025, 33 week primary outcome) is listed on ClinicalTrials.gov as Phase 1, with a primary outcome of "Evaluate the Safety and Tolerability VK2735" over "33 weeks". source

   Our view: A 13-patient arm labeled exploratory is a thin base for a headline number, and the registered primary outcome is safety, not weight. The 78-week VANQUISH trials will be the real test of whether weight loss keeps going.

2. Science · weight medium

   "Up to 97%" is the best of several small cohorts

   The company said: "Up to 97% of Weight Loss Maintained Following Transition to Every Other Week Dosing for Three Months" source

   The record says: The release table shows the combined every-other-week group (n=37) maintaining 90% of week 21 weight loss against 61% for placebo (n=27). The 97% figure belongs to the 17.5 mg weekly to 10.0 mg every-other-week cohort of 12 patients. The maintenance period was 12 weeks. source

   Our view: The direction is clear and the placebo gap is large. But 97% is the top of a range from 83% to 97% across cohorts of 12 or 13, over three months, so durability beyond that is unproven.

3. Press release vs filing · weight medium

   Oral tolerability described two ways

   The company said: "in the dose range that Viking plans to explore in future studies, the company believes the results showed no meaningful difference in gastrointestinal (GI)-related adverse events between subjects treated with VK2735 and placebo." source

   The record says: Viking's October 14 release on the same 13-week Phase 2 oral trial (NCT06828055, 280 patients) says "Gastrointestinal (GI)-related events were the most commonly observed TEAEs and were consistent with the known effects of dual GLP-1 /GIP receptor agonists" and that "98% of reported drug-related treatment-emergent adverse events (TEAEs) characterized as mild or moderate". Neither release reviewed gives a discontinuation rate for the oral study. source

   Our view: The July wording is limited to a chosen dose range, and the October wording says GI events were the most commonly observed adverse events, consistent with the class, and that they generally occurred early and subsided with continued dosing. Phase 3 will use 27.5, 35 and 55 mg doses for 68 weeks, and neither release gives a discontinuation rate for the Phase 2 study.

4. Press release vs filing · weight medium

   Cash headline, buyback and then a large raise

   The company said: "Strong Quarter-End Cash Position of $502 Million" source

   The record says: The 10-Q says cash will "be sufficient to fund our operations through at least September 30, 2027" and that in July 2026 the board authorized a repurchase program to "purchase up to $500.0 million in shares of our common stock over a period of up to three years". Cash had fallen from $706 million at December 31, 2025 to $502 million, per the release. An 8-K filed on September 28, 2026 for offerings that closed on September 25 reported net proceeds of about $297.0 million from stock at $35.00 a share and about $250.8 million from convertible notes. source

   Our view: None of the four releases mentions the buyback authorization, and the July release does not state a runway date. The buyback authorization took effect July 30, and the offerings priced on September 23 produced about $548 million of combined net proceeds. The 10-Q says the company has no obligation to repurchase any amount under the program.

5. Press release vs filing · weight low

   Phase 3 "initiation" versus the registry

   The company said: "today announced the initiation of the SUNRISE Phase 3 clinical program for oral VK2735" source

   The record says: ClinicalTrials.gov, last updated October 16, 2026, lists SUNRISE-1 (NCT07868835) as NOT_YET_RECRUITING with an estimated start of November 2026. The October 14 release also carries a correction note saying its October 6 release "incorrectly stated" the design of the oral maintenance study. source

   Our view: "Initiation" appears to mean the program is launched, not that patients are dosed. The distinction is small, and the correction note says the October 6 release incorrectly stated that the maintenance trial would evaluate weekly oral doses.

6. Legal and disclosure record · weight medium

   Ligand license dispute and Ascletis trade secret case

   The record says: The 10-Q states: "On April 24, 2026, Ligand notified us that Ligand is purporting to terminate Ligand's license of the TR-Beta Program to us under the Master License Agreement." It adds that Ligand filed a complaint in the Superior Court of California, County of San Diego on May 19, 2026, that Viking cross-complained on July 2, 2026, and that if Ligand prevails Viking would "lose certain intellectual property rights, including the right to develop or commercialize VK2809 and VK0214." The 10-Q adds that Viking believes it has "good and substantial defenses to the claims asserted by Ligand". It also describes Viking's own 2022 trade secret suit against Ascletis in the Southern District of California, which is stayed while a related ITC decision is on appeal at the Federal Circuit. No securities litigation or enforcement is disclosed in the latest filing. source

   Our view: VK2735 is not part of the Ligand dispute, but the four releases reviewed do not mention it, and the October 14 boilerplate still lists VK2809 and VK0214 as programs. The Ascletis case is one Viking brought: the 10-Q says the full ITC affirmed the substantial majority of the determinations in favor of Viking, and both sides have appealed to the Federal Circuit.

This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our right of reply.